In 2014 GEROPHARM, Group of Companies presented new generic drug Memantinol indicated for treatment of moderate and severe Alzheimer’s dementia. The drug improves cognitive processes and increases daily activity. Memantinol enters the Russian market with the slogan “Dementia: not a reason for refreshing.”
This spring the company introduced a new pharmaceutical form of
Memantinol to the market. Product package now contains 20 tablets. This
pharmaceutical form is convenient for initial treatment of dementia. At
the beginning of Memantinol use a patient shall take only 20 tablets to
choose dosage and evaluate its tolerability. Such pharmaceutical form
(20 tablets) is an optimal choice at the initial treatment stage.
Product package is cost effective in comparison with other
pharmaceutical forms and balanced in terms of tablets quantity because
it allows a physician to assess therapy progress and chose further
Development of neurological direction is a priority activity for GEROPHARM, Group of Companies. Product portfolio of the company contains such original drugs as Cortexin (effectiveneuroprotector) and Cortexin for children (pharmaceutical form developed for paediatric treatment). In 2013 the company introduced Levetinol (new effective antiepileptic drug) to the market.
Nowadays the company have more than 15 drug products at different stages of development. They refer to both current and new directions of the company’s activity. Three projects are developed under federal target programs of the Ministry of Industry and Trade of the Russian Federation and the Ministry of the Education of the Russian Federation. They include projects for the development of a producing strain and technologies of analogue insulins production.